The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from CNW Group

Welichem announces the Resignation of Lijuan Pang as a Director

Friday, March 01, 2013

Welichem announces the Resignation of Lijuan Pang as a Director19:35 EST Friday, March 01, 2013BURNABY, BC, March 1, 2013 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Mrs. Lijuan Pang has resigned as a director of the Company effective March 1, 2013.The Company has valued the contribution of Mrs. Pang as a director of the Company over the past one and half years and wishes her success in her future endeavours.About Welichem Biotech Inc. Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer. For a more complete business and financial profile of the Company, interested parties are encouraged to visit the Company's website, TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.SOURCE: Welichem Biotech Inc.For further information: Liren Tang, President and Chief Executive Officer of the Company: Tel.: (604) 432-1703, Email: